Bavarian Nordic reports promising results for RSV vaccine in phase II trial

On Wednesday morning, Bavarian Nordic announced positive results for the company’s RSV vaccine candidate. According to the biotech company, the candidate has shown an efficacy rate of up to 79 percent in the reduction of symptomatic RSV infections in a phase II trial.


The positive news just keeps on coming for Bavarian Nordic.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs